About US
Contact us
-
NICE signs off on Merck's Keytruda for early-stage triple negative breast cancerMonths after offeringMerck’s Keytrudarestricted coverage for previously untreated metastatic triple-negative breast cancer (TNBC), England’s drug cost watchdog has signed off on the drug’s use agains2022/11/8
-
Moderna's Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study saysIt’s been nearly two years since Moderna’s COVID-19 vaccine made its debut in the U.S., but research on the shot is far from over. Now, a new study has flagged higher risks of heart inflammation asso2022/11/8
-
SK bioscience plans global expansion push focused on vaccine manufacturing, gene therapy and moreAmid a global expansion push, SK bioscience has unveiled agrowth strategyfocused on broadeningits reach in vaccine manufacturing and R&D. Going forward, the company plans to focus on respondin2022/11/4
-
Moderna slashes billions from its sales forecast after a quarter of 'pain points'When Modernareacheda deal with the European Commission to delay some shipments of its COVID-19 vaccine to 2023, the company wasn’t certain how the development would affectsales projections for the sh2022/11/4
-
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapiesThe high cost of gene therapies has proved a sticking point for the personalized medicines in recent years, most notably prompting bluebird bio to withdraw its blood disorder treatment Zynteglo in Eu2022/11/2
-
Gilead's Vemlidy enters the pediatric hepatitis B arena with FDA green lightAmid Gilead Science’s oncology push, the company hasn’t forgotten about its hepatitis portfolio. The latest evidence? Gilead's chronic hepatitis B virus (HBV) drug Vemlidy scored a new indication to2022/11/2
-
GSK's Shingrix rebound rolls on with record sales, but looming Zantac lawsuits raise M&A doubtsIn GSK’s first quarter after the Haleon consumer health spinoff, shingles vaccine Shingrix put up another record show. But while a cloud of Zantac lawsuits gathers over the company, CEO Emma Walmsley2022/10/31
-
Alkermes joins Bristol Myers in IL-2 exit with oncology business spinoffInstead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.”2022/10/31
-
GSK's oral anemia drug bruised with FDA panel partial snub in chronic kidney diseaseFollowing two FDA rejections of novel oral anemia drugs, all eyes are on GSK’s daprodustat. Now, the drug has come out of an FDA panel meeting partially bruised, losing experts' support in one of the2022/10/27
-
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO saysEven as Revlimid generics chip away at Bristol Myers Squibb's top line, the companyremains confident it can shepherd its roster of new drugs toward more than $25 billion in revenues by 2029, executiv2022/10/27